Posted by Michael Wonder on 27 Jan 2018
Repros announces negative opinion from the EMA for enclomiphene
26 January 2018 - Repros Therapeutics today announced that, consistent with the previously disclosed guidance from the EMA, the CHMP, a committee of the EMA, has formally issued a negative opinion for the centralised marketing authorisation application for enclomiphene for the treatment of secondary hypogonadism previously submitted to the EMA by the Company's U.K. subsidiary, Renable Pharma Limited.
